Vernal Biosciences is aiming to democratize access to mRNA manufacturing technologies, with the goal of accelerating the clinical impact of mRNA as a foundational therapeutic modality.
Vernal is focused on achieving and maintaining high purity throughout the scaling of all mRNA manufacturing processes for clients in the research and ultimately clinical stages. The company wants to accelerate client projects and simplify regulatory interactions, enabling clients to focus on other high-value operations such as target biology, drug discovery, and clinical development.
The company’s founder and CEO, Christian Cobaugh, is a veteran of the mRNA industry, leading drug discovery projects as the first Alexion Pharmaceuticals researcher in the Alexion-Moderna partnership, then leading the mRNA program (internal pipeline, Ultragenyx partnership) at Arcturus Therapeutics, and heading mRNA drug discovery and process development at Translate Bio.
Vernal currently offers manufacturing-research-use mRNA and is scaling its manufacturing process that will become an advanced staging ground for clinical manufacturing projects. The company’s mission is to remove barriers to mRNA manufacturing technologies for the benefit of patients and investors seeking novel use cases of mRNA, with equal access to high purity mRNA manufacturing encouraging growth in innovation, competition, and collaboration.